Cullinan offers promising oncology and autoimmune products, strong financials, and potential for growth, making it a ...

Tuspetinib based TUS+VEN+AZA triplet therapy is being advanced in the TUSCANY Phase 1/2 trial with the goal of creating an improved frontline therapy for newly diagnosed AML patients that is active ...

The biotherapeutics company said the treatment, LYT-200, is being evaluated in two ongoing clinical trials. It was previously granted orphan drug designation for the treatment of acute myeloid ...

Acute myeloid leukemia (AML) is an aggressive bone marrow disease. Despite advances in treatment, AML remains a therapeutic challenge due to high rates of ...

(Alliance News) - PureTech Health PLC on Thursday said that the US Food & Drug Administration has granted fast track designation to its antibody LYT-200 for the treatment of acute myeloid leukemia.

Biotherapeutics company PureTech Health plc (PRTC) announced Thursday that the U.S. Food and Drug Administration (FDA) has granted ...

Patients with myelofibrosis who cleared driver mutations within 30 days after hematopoietic stem cell transplantation ...

A study published in the journal Molecules highlights the potential of two cannabis-derived compounds, cannabinol (CBN) and cannabigerol (CBG), in combating acute myeloid leukemia. “Several cannabis ...

A young man has been diagnosed with acute stage 3 leukemia and urgently needs help to survive. He has appealed to the general ...

Researchers explored the risks for basal cell carcinoma, squamous cell carcinoma, and melanoma in patients who underwent BMT.

The cancer fund was founded by and in named in honor of the late Marie Mazziotta, Mark and Bob’s sister, who died in 2006 at ...

CEO Bruce C. Cozadd sold 1,500 shares of the company’s stock in a transaction dated Thursday, January 2nd. The shares were ...